Sanofi (NASDAQ:SNY) Shares Acquired by ORG Partners LLC

ORG Partners LLC raised its position in shares of Sanofi (NASDAQ:SNY) by 17.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,681 shares of the company’s stock after buying an additional 253 shares during the quarter. ORG Partners LLC’s holdings in Sanofi were worth $81,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. Barrow Hanley Mewhinney & Strauss LLC raised its stake in Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after acquiring an additional 3,164,092 shares during the period. Franklin Resources Inc. raised its position in shares of Sanofi by 13.1% during the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after purchasing an additional 395,744 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of Sanofi by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after purchasing an additional 246,224 shares during the last quarter. Natixis Advisors LLC boosted its position in Sanofi by 4.1% during the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock valued at $165,640,000 after purchasing an additional 114,133 shares during the period. Finally, Raymond James & Associates grew its stake in Sanofi by 4.8% during the 3rd quarter. Raymond James & Associates now owns 2,819,348 shares of the company’s stock worth $162,479,000 after buying an additional 129,472 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Trading Down 1.0 %

Shares of SNY stock opened at $48.73 on Friday. The firm has a market capitalization of $123.67 billion, a PE ratio of 24.86, a price-to-earnings-growth ratio of 1.23 and a beta of 0.57. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The stock has a fifty day moving average of $48.70 and a two-hundred day moving average of $52.08.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. The firm had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. Sanofi’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter last year, the company earned $2.55 EPS. As a group, research analysts expect that Sanofi will post 4.06 EPS for the current year.

Analysts Set New Price Targets

SNY has been the subject of several analyst reports. Citigroup raised shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Sanofi currently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.